121800 Advanced Glycation Endproduct-BSA

121800
Le prix n'a pas pu être récupéré
La quantité minimale doit être un multiple de
À la validation de la commande Plus d'informations
Vous avez sauvegardé ()
 
Demander le prix
Disponibilité limitéeDisponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service
      Voir les Prix & la Disponibilité
      Click To Print This Page

      Aperçu

      Replacement Information

      Prix & Disponibilité

      RéférenceDisponibilité Conditionnement Qté Prix Quantité
      121800-10MG
      Récupération des données relatives à la disponibilité...
      Disponibilité limitéeDisponibilité limitée
      En stock 
      Interrompu(e)
      Disponible en quantités limitées
      Disponibilité à confirmer
        Pour le restant : Nous vous tiendrons informé
          Pour le restant : Nous vous tiendrons informé
          Nous vous tiendrons informé
          Contacter le Service Clients
          Contact Customer Service

          Flacon en verre 10 mg
          Prix en cours de récupération
          Le prix n'a pas pu être récupéré
          La quantité minimale doit être un multiple de
          À la validation de la commande Plus d'informations
          Vous avez sauvegardé ()
           
          Demander le prix
          Description
          OverviewPrepared by reacting BSA with glycoaldehyde under sterile conditions. Glycated-BSA shows a 5,000 - 10,000% increase in fluorescence as compared to normal BSA (confirmed by fluorescence spectrophotometry, excitation/emission 370/440 nm). AGE-BSA has been reported to induce apoptosis in cultured human umbilical vein endothelial cells and inhibit nitric oxide synthase activity in proximal tubular epithelial cells. Advanced glycation end products and their receptors have been implicated in the pathogenesis of diabetes, induction of proinflammatory cytokines, and stimulation of smooth muscle proliferation, and fibronectin production.
          Catalogue Number121800
          Brand Family Calbiochem®
          SynonymsAGE-BSA
          References
          ReferencesOkamoto, T., et al. 2002. Microvasc. Res. 63, 186.
          Ohgami, N., et al. 2001. J. Biol. Chem. 276, 3195.
          Wang, R., et al. 2001. J. Nippon Med. Sch. 68, 472.
          Sakata, N., et al. 2000. J. Atheroscler. Thromb. 7, 169.
          Verbeke, P., et al. 2000. Biochim. Biophys. Acta 1502, 481.
          Farboud, B., et al. 1999. Mol. Vis. 5, 11.
          Huang, J.-S., et al. 1999. Biochem. J. 342, 231.
          Min, C., et al. 1999. Diabetes Res. Clin. Pract. 46, 197.
          Neumann, A., et al. 1999. FEBS Lett. 453, 283.
          Stitt, A.W., et al. 1999. Biochem. Biophys. Res. Commun. 256, 549.
          Nazaimoon, W. and Bak, K. 1998. Malays. J. Pathol. 20, 83.
          Product Information
          FormLiquid
          FormulationIn sterile-filtered PBS.
          Applications
          Biological Information
          Purity≥95% by SDS-PAGE
          Concentration Label Please refer to vial label for lot-specific concentration
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Dry Ice Only
          Toxicity Standard Handling
          Storage ≤ -70°C
          Avoid freeze/thaw Avoid freeze/thaw
          Do not freeze Ok to freeze
          Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          FDS

          Titre

          Fiche de données de sécurité des matériaux (FDS) 

          Certificats d'analyse

          TitreNuméro de lot
          121800

          Références bibliographiques

          Aperçu de la référence bibliographique
          Okamoto, T., et al. 2002. Microvasc. Res. 63, 186.
          Ohgami, N., et al. 2001. J. Biol. Chem. 276, 3195.
          Wang, R., et al. 2001. J. Nippon Med. Sch. 68, 472.
          Sakata, N., et al. 2000. J. Atheroscler. Thromb. 7, 169.
          Verbeke, P., et al. 2000. Biochim. Biophys. Acta 1502, 481.
          Farboud, B., et al. 1999. Mol. Vis. 5, 11.
          Huang, J.-S., et al. 1999. Biochem. J. 342, 231.
          Min, C., et al. 1999. Diabetes Res. Clin. Pract. 46, 197.
          Neumann, A., et al. 1999. FEBS Lett. 453, 283.
          Stitt, A.W., et al. 1999. Biochem. Biophys. Res. Commun. 256, 549.
          Nazaimoon, W. and Bak, K. 1998. Malays. J. Pathol. 20, 83.

          Brochure

          Titre
          Caspases and other Apoptosis Related Tools Brochure
          Pathways and Biomarkers of Oxidative Stress
          Fiche technique

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision08-April-2008 RFH
          SynonymsAGE-BSA
          DescriptionPrepared by reacting bovine serum albumin (BSA) with glycoaldehyde under sterile conditions. Fluorescence of AGE-BSA is confirmed by fluorescence spectrophotometry, excitation/emission = 370/440 nm. Glycated BSA shows a 5000-10,000% increase in fluorescence compared to control BSA. AGE and their receptors have been implicated in the pathogenesis of diabetes, induction of pro-inflammatory cytokines, and stimulation of smooth muscle proliferation and fibronectin production. AGE-BSA has also been shown to induce apoptosis in cultured human umbilical vein endothelial cells (HUVEC) and inhibit nitric oxide synthase activity in proximal tubular epithelial cells of the kidney.
          FormLiquid
          FormulationIn sterile-filtered PBS.
          Concentration Label Please refer to vial label for lot-specific concentration
          Purity≥95% by SDS-PAGE
          Storage ≤ -70°C
          Avoid freeze/thaw
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
          Toxicity Standard Handling
          ReferencesOkamoto, T., et al. 2002. Microvasc. Res. 63, 186.
          Ohgami, N., et al. 2001. J. Biol. Chem. 276, 3195.
          Wang, R., et al. 2001. J. Nippon Med. Sch. 68, 472.
          Sakata, N., et al. 2000. J. Atheroscler. Thromb. 7, 169.
          Verbeke, P., et al. 2000. Biochim. Biophys. Acta 1502, 481.
          Farboud, B., et al. 1999. Mol. Vis. 5, 11.
          Huang, J.-S., et al. 1999. Biochem. J. 342, 231.
          Min, C., et al. 1999. Diabetes Res. Clin. Pract. 46, 197.
          Neumann, A., et al. 1999. FEBS Lett. 453, 283.
          Stitt, A.W., et al. 1999. Biochem. Biophys. Res. Commun. 256, 549.
          Nazaimoon, W. and Bak, K. 1998. Malays. J. Pathol. 20, 83.